Macrogen Inc (038290) - Total Assets
Based on the latest financial reports, Macrogen Inc (038290) holds total assets worth ₩341.60 Billion KRW (≈ $231.50 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Macrogen Inc book value and equity for net asset value and shareholders' equity analysis.
Macrogen Inc - Total Assets Trend (2011–2024)
This chart illustrates how Macrogen Inc's total assets have evolved over time, based on quarterly financial data.
Macrogen Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Macrogen Inc's total assets of ₩341.60 Billion consist of 34.0% current assets and 66.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩33.05 Billion | 10.0% |
| Accounts Receivable | ₩39.61 Billion | 12.0% |
| Inventory | ₩21.49 Billion | 6.5% |
| Property, Plant & Equipment | ₩106.16 Billion | 32.2% |
| Intangible Assets | ₩13.38 Billion | 4.1% |
| Goodwill | ₩26.89 Billion | 8.2% |
Asset Composition Trend (2011–2024)
This chart illustrates how Macrogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 038290 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Macrogen Inc's current assets represent 34.0% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 10.0% of total assets in 2024, up from 8.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 32.2% of total assets.
Macrogen Inc Competitors by Total Assets
Key competitors of Macrogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
Macrogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 0.73 | 1.66 |
| Quick Ratio | 0.64 | 0.54 | 1.44 |
| Cash Ratio | 0.00 | 0.19 | 0.00 |
| Working Capital | ₩-18.61 Billion | ₩-29.15 Billion | ₩38.30 Billion |
Macrogen Inc - Advanced Valuation Insights
This section examines the relationship between Macrogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 27.9% |
| Total Assets | ₩329.66 Billion |
| Market Capitalization | $110.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Macrogen Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Macrogen Inc's assets grew by 27.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Macrogen Inc (2011–2024)
The table below shows the annual total assets of Macrogen Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩329.66 Billion ≈ $223.41 Million |
+27.87% |
| 2023-12-31 | ₩257.82 Billion ≈ $174.72 Million |
-7.96% |
| 2022-12-31 | ₩280.13 Billion ≈ $189.84 Million |
-6.99% |
| 2021-12-31 | ₩301.18 Billion ≈ $204.10 Million |
+4.65% |
| 2020-12-31 | ₩287.79 Billion ≈ $195.03 Million |
+27.61% |
| 2019-12-31 | ₩225.53 Billion ≈ $152.84 Million |
+25.64% |
| 2018-12-31 | ₩179.50 Billion ≈ $121.64 Million |
+0.44% |
| 2017-12-31 | ₩178.71 Billion ≈ $121.11 Million |
+12.03% |
| 2016-12-31 | ₩159.52 Billion ≈ $108.11 Million |
+18.77% |
| 2015-12-31 | ₩134.31 Billion ≈ $91.02 Million |
+15.61% |
| 2014-12-31 | ₩116.18 Billion ≈ $78.73 Million |
+32.45% |
| 2013-12-31 | ₩87.71 Billion ≈ $59.44 Million |
+6.81% |
| 2012-12-31 | ₩82.12 Billion ≈ $55.65 Million |
+42.19% |
| 2011-12-31 | ₩57.75 Billion ≈ $39.14 Million |
-- |
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more